Claims
- 1. A compound having the formula ##STR8## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.2 is hydrogen, straight-chain and branched C.sub.1 -C.sub.10 alkyl, cyclohexylmethyl or --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, or furanyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy and trifluoromethyl;
- m is 1-5;
- n is 1 or 2;
- R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- Y is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy;
- or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1 which is 4-(2-benzylamino-ethoxy)-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 3. A compound according to claim 1 which is 4-[2-(4-methyl-benzylamino)-ethoxy]-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 4. A compound according to claim 1 which is 4(7)-(2-benzylamino-ethoxy)-1-(3)-methyl-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 5. A compound according to claim 1 which is 4-(3-benzylamino-propoxy)-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 6. A compound according to claim 1 which is 4-{2-[(naphthalen-1-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 7. A compound according to claim 1 which is 4-[2-(4-tert-butyl-benzylamino)-ethoxy]-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 8. A compound according to claim 1 which is 4-{2-[(thiophen-2-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 9. A compound according to claim 1 which is 4-[2-(4-chloro-benzylamino)-ethoxy]-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 10. A compound according to claim 1 which is 4-(2-benzylamino-ethoxy)-6-chloro-1,3-dihydrobenzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 1 which is 6-Chloro-4-{2-[(thiophen-2-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 12. A compound according to claim 1 which is 6-Chloro-4-{2-[(thiophen-3-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 13. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to the formula ##STR9## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.2 is hydrogen, straight-chain and branched C.sub.1 -C.sub.10 alkyl, cyclohexylmethyl or --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, or furanyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy and trifluoromethyl;
- m is 1-5;
- n is 1 or 2;
- R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- Y is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy;
- or a pharmaceutically acceptable salt thereof.
Parent Case Info
This application claims benefit of priority of provisional application No. 60/038,682 filed Feb. 18, 1997.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4140789 |
Jaeggi |
Feb 1979 |
|
5750556 |
Mewshaw et al. |
May 1998 |
|
5760070 |
Mewshaw et al. |
Jun 1998 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
707007 |
Apr 1996 |
EPX |
771801 |
May 1997 |
EPX |
WO9208708 |
May 1992 |
WOX |
WO9323385 |
Nov 1993 |
WOX |
WO9808819 |
Mar 1998 |
WOX |
WO9808843 |
Mar 1998 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Joseph Weinstock et al., J. Med. Chem., 30, 1166-1176 (1987). |
Juan C. Jaen et al., J. Med. Chem., 31, 1621-1625 (1988). |
Staehelin et al., J. Biological Chemistry 258 (6) 3496-3502,1983. |